Alexion reports revenue up, profit down on restructuring costs

ALEXION PHARMACEUTICALS reported a 17 percent decline in profit for the 2017 third quarter as the company's expenses rose on restructuring and its cost of sales. Above, the Alexion manufacturing facility in Smithfield, which the company remains committed to closing as part of its corporate restructuring. / COURTESY ALEXION
ALEXION PHARMACEUTICALS reported a 17 percent decline in profit for the 2017 third quarter as the company's expenses rose on restructuring and its cost of sales. Above, the Alexion manufacturing facility in Smithfield, which the company remains committed to closing as part of its corporate restructuring. / COURTESY ALEXION
SMITHFIELD – New Haven, Conn.-based Alexion Pharmaceuticals Inc. reported a 17 percent year-over-year decline in net income for the 2017 third quarter to $78 million, or 35 cents per diluted share, which fell 7 cents over the year. The biopharmaceutical company that focuses on drugs for rare diseases increased third-quarter revenue by 7.5 percent year…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -